159. 色素性乾皮症 Xeroderma pigmentosum Clinical trials / Disease details


臨床試験数 : 11 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-001419-10-ES
(EUCTR)
31/01/202217/11/2021Study to evaluate the safety and the efficacy of the photoprotective drug, afamelanotide in patients with Xeroderma Pigmentosum C and VA Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV) - Phase IIa XPC and XPV Study Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SCENESSE
Product Name: Afamelanotide (16 mg implant)
CLINUVEL EUROPE LIMITEDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
6Phase 2Belgium;Spain
2EUCTR2021-001419-10-BE
(EUCTR)
16/11/2021Study to evaluate the safety and efficacy of the photoprotective drug, afamelanotide in patients with Xeroderma Pigmentosum C and VA Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV) - Phase IIa XPC and XPV Study Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SCENESSE
Product Name: Afamelanotide (16 mg implant)
CLINUVEL EUROPE LIMITEDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
6Phase 2Spain;Belgium